Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Clicks: 203
ID: 80682
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
nakagawa2020finallung Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nakagawa, K.
Journal lung cancer (amsterdam, netherlands)
Year 2020
DOI
10.1016/j.lungcan.2019.11.025
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.